Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug

International Journal of Clinical Practice

Volumn 58, Issue 7, 2004, Pages 706-713

  Carlson, Lars A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cholesterol; Free fatty acids; Niaspan; Nicotinic acid; Treatment; Triglycerides

Indexed keywords

ANTICOAGULANT AGENT; ANTIOXIDANT; CLOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; RESIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN;

AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; FOOD DRUG INTERACTION; GOUT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICOSURIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; LIVER TOXICITY; MONOTHERAPY; MYALGIA; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; STRUCTURE ACTIVITY RELATION; SUSTAINED RELEASE PREPARATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOLYSIS; MALE; NIACIN; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 4344592577     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00233.x     Document Type: Article

References (26)

1. Carlson LA. The broad spectrum hypolipidaemic drug nicotinic acid. J Drug Dev 1990; 3 (Suppl 1): 223-6.
2. LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary disease. A meta analysis of randomised controlled studies. JAMA 1999; 282: 2340-6.
3. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomised, placebo-controlled trial. Lancet 2002; 360: 7-22.
4. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81.
5. Canner PL, Berge K, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55.
6. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18.
7. Brown BG, Zhao X-Q, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
8. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143-421.
9. Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; I: 16-9.
10. Barker P, Kastelein J, Nunn A et al. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003; 168: 195-211.
11. Hokanson J, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol: a meta analysis of papulation-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
12. Packard CJ, Petrie JR. The end of triglycerides in cardiovascular risk assessment. Br Med J 1998; 317: 553-4.
13. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54: 558-9.
14. Data on file. Protocol 91/18 and 91/19. Kos Pharmaceuticals, Miami, FF.
15. Data on file. Protocol 94/10. Kos Pharmaceuticals, Miami, FF.
16. Data on file. Protocol 94/08. Kos Pharmaceuticals, Miami, FF.
17. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47: 1097-104.
18. Morgan JM, Capuzzi DM, Guyton JR et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled study. J Cardiovasc Pharmacol Ther 1996; 1: 195-202.
19. Wolfe ML, Vartanian SF, Ross JL et al. Safety and effectiveness of Niaspan when added sequentially to a statin for the treatment of dyslipidemia. Am J Cardiol 2001; 87: 476-9.
20. Guyton JR, Goldberg AC, Kreisberg RA et al. Effectiveness of once-nightly dosing of extended release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82: 737-43.
21. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20: 1683-7.
22. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002; 162: 1568-76.
23. Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand 1962; 172: 641-5.
24. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963; 173: 719-22.
25. 3H-labeled nicotinic acid studied with autoradiography. Life Sci 1964; 3: 867-71.
26. Carlson LA, Orö L, Östman J. Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia during the first week of treatment. J Atheroscler Res 1968; 8: 667-77.